Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

Results from a multicenter prospective phase 2 clinical trial of patients with myelofibrosis demonstrated that those who received 6 months of 15-mg ruxolitinib treatment prior to allogenic hematopoietic transplantation had a high rate of transplantation (92%). The study also showed 55% 1-year disease-free survival among all patients. Those with an HLA-matched sibling donor had a 1-year disease-free survival of 83%, versus 40% and 34%, respectively, for patients with an HLA-matched or -mismatched unrelated donor.